Latest Industry Insights

We talked to Dr. Emily Leproust, CEO of Twist Bioscience, about her company's innovative offerings at the recent Advances in Genome Biology and Technology Conference (AGBT).

We spoke to Dr Gary Kruppa, Vice President Proteomics at Bruker Daltonics, about PASEF, a powerful new analysis technique which promises to maximize the potential of proteome analysis using LC-MS.

We spoke to Ping Yeh, CEO of StemoniX, to learn more about the company and their mission. With an aim to accelerate and optimize drug discovery and development, StemoniX creates ‘ready-to-use’ microtissue plates that mimic the native organ tissue.

BD Biosciences has developed a method with the potential to transform both single cell transcriptional profiling and high parameter proteomics

This article describes some new in vitro approaches to toxicology, as well as current initiatives, to facilitate the verification of methods and conclusions, and to enhance data sharing and scientific discovery.

We spoke to Dirk Löffert, Ph.D., CEO of Biomillenia, to learn about some of the challenges of isolating live bacterial species, and how microbiome-on-a-chip technology can help overcome some of these.

To learn about the importance of the extracellular matrix and some of the limitations of current organoid culture systems, we spoke to Colin Sanctuary, CEO and founder of QGel, a spin-out from EPFL.

Promoting the adoption of in vitro toxicity testing is an important undertaking, so we should strive to overcome the barriers preventing its widespread adoption. Already, collaborative efforts have made progress in this regard, and research advances are increasingly demonstrating the potential of in vitro biomimetic liver models.

The field of toxicology as a whole is at a crossroads where current and future technologies are enabling better predictions of toxicity before a substance is released for human consumption or exposure. While a few barriers remain, we are making progress towards overcoming them, from both technical and policy perspectives.

BioStatus develops and supplies products for cell-based imaging, cytometry and screening applications. We met with Roy Edward, Director at BioStatus during the High Content and Phenotypic Screening 2017 event to learn more.